Do analysts prefer DXR or CNXU?

Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 124.97%. Given Conexeu Sciences' higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Conexeu Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, DXR or CNXU?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Conexeu Sciences N/A N/A -$3.92M -$0.11 N/A

Is DXR or CNXU more profitable?

Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Conexeu Sciences N/A N/A N/A

Does the media refer more to DXR or CNXU?

In the previous week, Conexeu Sciences had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Conexeu Sciences and 1 mentions for Daxor. Conexeu Sciences' average media sentiment score of 0.82 beat Daxor's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer STIM or DXR?

Neuronetics currently has a consensus price target of $4.50, suggesting a potential upside of 50.00%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neuronetics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, STIM or DXR?

Daxor has lower revenue, but higher earnings than Neuronetics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neuronetics $149.16M 1.53 -$39M -$0.44 N/A Daxor N/A N/A N/A N/A N/A

Is STIM or DXR more profitable?

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% Daxor N/A N/A N/A

Does the media prefer STIM or DXR?

In the previous week, Neuronetics had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Neuronetics and 1 mentions for Daxor. Neuronetics' average media sentiment score of 1.20 beat Daxor's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DXR or PDEX?

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 6.59%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts plainly believe Pro-Dex is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pro-Dex 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has better valuation and earnings, DXR or PDEX?

Pro-Dex has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Pro-Dex $74.64M 2.81 $8.98M $3.62 18.14

Is DXR or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Pro-Dex 16.08% 22.78% 14.30%

Does the media refer more to DXR or PDEX?

In the previous week, Pro-Dex had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Daxor. Pro-Dex's average media sentiment score of 0.71 beat Daxor's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend DXR or OWLT?

Owlet has a consensus price target of $15.00, suggesting a potential upside of 186.81%. Given Owlet's higher probable upside, analysts plainly believe Owlet is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Owlet 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, DXR or OWLT?

Daxor has higher earnings, but lower revenue than Owlet. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor N/A N/A N/A N/A N/A Owlet $105.70M 1.45 -$39.68M -$0.75 N/A

Is DXR or OWLT more profitable?

Daxor has a net margin of 0.00% compared to Owlet's net margin of -8.61%. Daxor's return on equity of 0.00% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Owlet -8.61% -601.24% -15.96%

Does the media refer more to DXR or OWLT?

In the previous week, Owlet had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Owlet and 1 mentions for Daxor. Owlet's average media sentiment score of 0.86 beat Daxor's score of 0.00 indicating that Owlet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Owlet 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FOCL or DXR?

FocalTherics currently has a consensus target price of $7.75, suggesting a potential upside of 87.65%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FocalTherics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.40 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, FOCL or DXR?

Daxor has lower revenue, but higher earnings than FocalTherics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio FocalTherics $70.53M 2.19 -$29.25M -$1.03 N/A Daxor N/A N/A N/A N/A N/A

Is FOCL or DXR more profitable?

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets FocalTherics -56.26% -248.00% -44.69% Daxor N/A N/A N/A

Does the media prefer FOCL or DXR?

In the previous week, FocalTherics had 21 more articles in the media than Daxor. MarketBeat recorded 22 mentions for FocalTherics and 1 mentions for Daxor. FocalTherics' average media sentiment score of 1.25 beat Daxor's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment FocalTherics 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Daxor (DXR) Competitors

$10.00 -0.30 (-2.91%)

As of 08/21/2026 01:35 PM Eastern

Compare

DXR vs. CNXU, STIM, PDEX, OWLT, and FOCL

Should you buy Daxor stock or one of its competitors? Daxor's main competitors and comparable companies include Conexeu Sciences (CNXU), Neuronetics (STIM), Pro-Dex (PDEX), Owlet (OWLT), and FocalTherics (FOCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Daxor compare to Conexeu Sciences?

Daxor (NASDAQ:DXR) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A

1.3% of Daxor shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Conexeu Sciences had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Conexeu Sciences and 1 mentions for Daxor. Conexeu Sciences' average media sentiment score of 0.82 beat Daxor's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Conexeu Sciences has a consensus price target of $20.00, indicating a potential upside of 124.97%. Given Conexeu Sciences' higher possible upside, analysts clearly believe Conexeu Sciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Conexeu Sciences	N/A	N/A	N/A

Summary

Daxor and Conexeu Sciences tied by winning 3 of the 6 factors compared between the two stocks.

How does Daxor compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

53.6% of Neuronetics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 8.4% of Neuronetics shares are held by insiders. Comparatively, 51.5% of Daxor shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Neuronetics had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Neuronetics and 1 mentions for Daxor. Neuronetics' average media sentiment score of 1.20 beat Daxor's score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neuronetics currently has a consensus price target of $4.50, suggesting a potential upside of 50.00%. Given Neuronetics' higher possible upside, research analysts clearly believe Neuronetics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has lower revenue, but higher earnings than Neuronetics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.53	-$39M	-$0.44	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

Neuronetics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Daxor has a net margin of 0.00% compared to Neuronetics' net margin of -19.62%. Daxor's return on equity of 0.00% beat Neuronetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
Daxor	N/A	N/A	N/A

Summary

Neuronetics beats Daxor on 7 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 51.5% of Daxor shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pro-Dex has a consensus target price of $70.00, suggesting a potential upside of 6.59%. Given Pro-Dex's stronger consensus rating and higher possible upside, analysts plainly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Pro-Dex had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Daxor. Pro-Dex's average media sentiment score of 0.71 beat Daxor's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Daxor has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Pro-Dex	$74.64M	2.81	$8.98M	$3.62	18.14

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

Summary

Pro-Dex beats Daxor on 10 of the 12 factors compared between the two stocks.

How does Daxor compare to Owlet?

Daxor (NASDAQ:DXR) and Owlet (NYSE:OWLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Owlet has a consensus price target of $15.00, suggesting a potential upside of 186.81%. Given Owlet's higher probable upside, analysts plainly believe Owlet is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Daxor has higher earnings, but lower revenue than Owlet.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Owlet	$105.70M	1.45	-$39.68M	-$0.75	N/A

Daxor has a net margin of 0.00% compared to Owlet's net margin of -8.61%. Daxor's return on equity of 0.00% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Owlet	-8.61%	-601.24%	-15.96%

Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Owlet has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market.

1.3% of Daxor shares are held by institutional investors. Comparatively, 72.6% of Owlet shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 36.2% of Owlet shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Owlet had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Owlet and 1 mentions for Daxor. Owlet's average media sentiment score of 0.86 beat Daxor's score of 0.00 indicating that Owlet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Owlet	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Owlet beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to FocalTherics?

FocalTherics (NASDAQ:FOCL) and Daxor (NASDAQ:DXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Daxor has lower revenue, but higher earnings than FocalTherics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FocalTherics	$70.53M	2.19	-$29.25M	-$1.03	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

62.7% of FocalTherics shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 10.1% of FocalTherics shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Daxor has a net margin of 0.00% compared to FocalTherics' net margin of -56.26%. Daxor's return on equity of 0.00% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FocalTherics	-56.26%	-248.00%	-44.69%
Daxor	N/A	N/A	N/A

FocalTherics has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Daxor has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

FocalTherics currently has a consensus target price of $7.75, suggesting a potential upside of 87.65%. Given FocalTherics' higher probable upside, analysts plainly believe FocalTherics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, FocalTherics had 21 more articles in the media than Daxor. MarketBeat recorded 22 mentions for FocalTherics and 1 mentions for Daxor. FocalTherics' average media sentiment score of 1.25 beat Daxor's score of 0.00 indicating that FocalTherics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FocalTherics	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

FocalTherics and Daxor tied by winning 6 of the 12 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$58.38M	$6.02B	$7.37B	$12.85B
Dividend Yield	N/A	1.75%	2.54%	11.08%
P/E Ratio	N/A	26.67	272.88	24.24
Price / Sales	N/A	45.38	618.96	99.76
Price / Cash	N/A	33.24	78.62	53.99
Price / Book	N/A	6.23	13.05	6.20
Net Income	N/A	$150.07M	$3.47B	$348.59M
7 Day Performance	-2.15%	0.69%	2.09%	0.08%
1 Month Performance	-4.32%	8.91%	6.64%	3.88%
1 Year Performance	-9.09%	8.07%	25.02%	16.98%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	1.3229 of 5 stars	$10.00 -2.9%	N/A	-9.1%	$58.38M	N/A	N/A	37	Upcoming Earnings Gap Down
CNXU Conexeu Sciences	3.8109 of 5 stars	$9.43 +5.2%	$20.00 +112.1%	N/A	$239.76M	N/A	N/A	4
STIM Neuronetics	3.936 of 5 stars	$3.09 -1.6%	$4.50 +45.6%	-11.8%	$239.26M	$155.10M	N/A	180	Positive News
PDEX Pro-Dex	1.5467 of 5 stars	$66.31 -0.9%	$70.00 +5.6%	+42.7%	$213.72M	$66.59M	18.32	140	News Coverage
OWLT Owlet	3.2241 of 5 stars	$5.62 -2.9%	$15.00 +166.9%	-30.5%	$169.19M	$105.70M	N/A	106	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors

DXR vs. CNXU, STIM, PDEX, OWLT, and FOCL

How does Daxor compare to Conexeu Sciences?

Summary

How does Daxor compare to Neuronetics?

Summary

How does Daxor compare to Pro-Dex?

Summary

How does Daxor compare to Owlet?

Summary

How does Daxor compare to FocalTherics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Daxor (DXR) Competitors

DXR vs. CNXU, STIM, PDEX, OWLT, and FOCL

How does Daxor compare to Conexeu Sciences?

Which has higher earnings and valuation, DXR or CNXU?

Do institutionals & insiders believe in DXR or CNXU?

Does the media refer more to DXR or CNXU?

Do analysts prefer DXR or CNXU?

Is DXR or CNXU more profitable?

Summary

How does Daxor compare to Neuronetics?

Do institutionals and insiders believe in STIM or DXR?

Does the media prefer STIM or DXR?

Do analysts prefer STIM or DXR?

Which has higher earnings and valuation, STIM or DXR?

Which has more volatility & risk, STIM or DXR?

Is STIM or DXR more profitable?

Summary

How does Daxor compare to Pro-Dex?

Do institutionals & insiders hold more shares of DXR or PDEX?

Do analysts prefer DXR or PDEX?

Does the media refer more to DXR or PDEX?

Which has more volatility and risk, DXR or PDEX?

Which has better valuation and earnings, DXR or PDEX?

Is DXR or PDEX more profitable?

Summary

How does Daxor compare to Owlet?

Do analysts recommend DXR or OWLT?

Which has better earnings and valuation, DXR or OWLT?

Is DXR or OWLT more profitable?

Which has more risk and volatility, DXR or OWLT?

Do insiders & institutionals hold more shares of DXR or OWLT?

Does the media refer more to DXR or OWLT?

Summary

How does Daxor compare to FocalTherics?

Which has preferable valuation & earnings, FOCL or DXR?

Do insiders and institutionals hold more shares of FOCL or DXR?

Is FOCL or DXR more profitable?

Which has more risk and volatility, FOCL or DXR?

Do analysts rate FOCL or DXR?

Does the media prefer FOCL or DXR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools